ES3001104T3 - Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias - Google Patents

Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias Download PDF

Info

Publication number
ES3001104T3
ES3001104T3 ES21765908T ES21765908T ES3001104T3 ES 3001104 T3 ES3001104 T3 ES 3001104T3 ES 21765908 T ES21765908 T ES 21765908T ES 21765908 T ES21765908 T ES 21765908T ES 3001104 T3 ES3001104 T3 ES 3001104T3
Authority
ES
Spain
Prior art keywords
compound
treatment
asthma
use according
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21765908T
Other languages
English (en)
Spanish (es)
Inventor
Palomino Laria Julio Castro-
Gomez Juan Camacho
Laria Nahomi Castro-Palomino
Alvarez Alina Ariosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Application granted granted Critical
Publication of ES3001104T3 publication Critical patent/ES3001104T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES21765908T 2020-08-21 2021-08-20 Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias Active ES3001104T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
ES3001104T3 true ES3001104T3 (es) 2025-03-04

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21765908T Active ES3001104T3 (es) 2020-08-21 2021-08-20 Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias

Country Status (20)

Country Link
US (1) US20230321053A1 (enExample)
EP (2) EP3957308A1 (enExample)
JP (1) JP7794807B2 (enExample)
KR (1) KR20230054444A (enExample)
CN (1) CN115942933A (enExample)
AU (1) AU2021327728A1 (enExample)
BR (1) BR112023002778A2 (enExample)
CA (1) CA3190081A1 (enExample)
DK (1) DK4199922T3 (enExample)
ES (1) ES3001104T3 (enExample)
FI (1) FI4199922T3 (enExample)
HR (1) HRP20241621T1 (enExample)
HU (1) HUE069338T2 (enExample)
LT (1) LT4199922T (enExample)
MX (1) MX2023002156A (enExample)
PL (1) PL4199922T3 (enExample)
PT (1) PT4199922T (enExample)
RS (1) RS66263B1 (enExample)
SI (1) SI4199922T1 (enExample)
WO (1) WO2022038261A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219223A1 (en) * 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
UA122670C2 (uk) * 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
HRP20211104T1 (hr) * 2017-03-06 2021-10-15 Palobiofarma, S.L. Aminska sol (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksilne kiseline

Also Published As

Publication number Publication date
WO2022038261A1 (en) 2022-02-24
US20230321053A1 (en) 2023-10-12
JP2023538419A (ja) 2023-09-07
MX2023002156A (es) 2023-03-01
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
LT4199922T (lt) 2025-01-10
EP4199922A1 (en) 2023-06-28
PT4199922T (pt) 2024-12-18
DK4199922T3 (da) 2024-11-25
EP3957308A1 (en) 2022-02-23
AU2021327728A1 (en) 2023-03-09
RS66263B1 (sr) 2024-12-31
CN115942933A (zh) 2023-04-07
CA3190081A1 (en) 2022-02-24
HUE069338T2 (hu) 2025-02-28
PL4199922T3 (pl) 2025-02-10
SI4199922T1 (sl) 2025-03-31
BR112023002778A2 (pt) 2023-03-14
FI4199922T3 (fi) 2024-12-05
HRP20241621T1 (hr) 2025-01-31
KR20230054444A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
ES2645368T3 (es) Terapias para mejorar la función pulmonar
US20220152057A1 (en) Methods and compositions for treating various disorders
Krouse et al. Asthma and the unified airway
Ohta et al. Japanese guideline for adult asthma
US9815894B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
Fujimura et al. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis
ES3001104T3 (es) Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
ES2779762T3 (es) Tratamiento de la alopecia areata
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
Weldon Gastroesophageal reflux disease and sinusitis: Their role in patients with chronic cough.
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
JP2022515615A (ja) 慢性炎症性腸疾患の治療のためのpar-1アンタゴニストの使用
CN119546306A (zh) 施用贝舒地尔以治疗慢性移植物抗宿主病的方法
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
ES2365533T3 (es) Combinación de andolast / glucocorticoides.
WO2026007876A1 (zh) Gpr84拮抗剂的用途
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途